November 2025: BactiQuant A/S has completed a directed share issue, raising gross proceeds of approximately DKK 16.3 million.
The transaction was announced on 4 November 2025 and carried out on 6 November 2025 as a directed capital increase without pre-emption rights for existing shareholders. The new shares were placed with a number of selected investors at market price.
The proceeds from the issue will be used to strengthen the company’s capital base and support its continued growth strategy, including a focus on the global pharma segment.
The capital increase was finally registered on 18 November 2025.